Atherosclerotic Cardiovascular Disease Clinical Trials

25 recruitingLast updated: June 21, 2026

There are 25 actively recruiting atherosclerotic cardiovascular disease clinical trials across 44 countries. Studies span Phase 3, Not Applicable, Phase 4, Phase 1, Phase 2, Early Phase 1. Top locations include Houston, Texas, United States, Miami, Florida, United States, Beijing, China. Updated daily from ClinicalTrials.gov.


Atherosclerotic Cardiovascular Disease Trials at a Glance

25 actively recruiting trials for atherosclerotic cardiovascular disease are listed on ClinicalTrialsFinder across 6 cities in 44 countries. The largest study group is Phase 3 with 8 trials, with the heaviest enrollment activity in Houston, Miami, and Beijing. Lead sponsors running atherosclerotic cardiovascular disease studies include Novartis Pharmaceuticals, Amgen, and CSL Behring.

Browse atherosclerotic cardiovascular disease trials by phase

Treatments under study

About Atherosclerotic Cardiovascular Disease Clinical Trials

Looking for clinical trials for Atherosclerotic Cardiovascular Disease? There are currently 14 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Atherosclerotic Cardiovascular Disease trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Atherosclerotic Cardiovascular Disease clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 25 trials

Recruiting
Phase 3

Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity

ObesityOverweightAtherosclerotic Cardiovascular Disease
Amgen12,800 enrolled774 locationsNCT07037433
Recruiting
Phase 3

Lp(a) Lowering Study of Pelacarsen (TQJ230) With Background Inclisiran in Participants With Elevated Lp(a) and Established ASCVD

Atherosclerotic Cardiovascular Disease (ASCVD)
Novartis Pharmaceuticals340 enrolled95 locationsNCT06813911
Recruiting
Phase 3

Pelacarsen Roll-over Extension Program

Atherosclerotic Cardiovascular Disease
Novartis Pharmaceuticals599 enrolled97 locationsNCT06875973
Recruiting
Phase 2Phase 3

Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis (POSIBIL6ESKD)

Atherosclerotic Cardiovascular Disease in Patients With ESKD
CSL Behring3,110 enrolled547 locationsNCT05485961
Recruiting
Phase 3

A Phase III Study To Evaluate the Efficacy And Safety Of HRS9531 In Participants With Atherosclerotic Cardiovascular Disease

Atherosclerotic Cardiovascular Disease
Fujian Shengdi Pharmaceutical Co., Ltd.9,262 enrolled1 locationNCT07551492
Recruiting
Phase 3

Assessing the Impact of Muvalaplin on Major Cardiovascular Events in Adults With Elevated Lipoprotein(a)

Atherosclerotic Cardiovascular Disease (ASCVD)Elevated Lp(a)
Eli Lilly and Company10,450 enrolled752 locationsNCT07157774
Recruiting
Phase 4

Dual PCSK9 Inhibition With Inclisiran and Alirocumab in Secondary Prevention

Atherosclerotic Cardiovascular Disease (ASCVD)Hypercholesterolemia
University Medical Centre Ljubljana60 enrolled1 locationNCT07581808
Recruiting
Phase 4

Study to Evaluate the Impact of a Targeted Lipid Optimization Program on LDL-C Control in At-risk Adult Patients With Dyslipidemia

Atherosclerotic Cardiovascular Disease
Novartis Pharmaceuticals326 enrolled1 locationNCT07034690
Recruiting

Aspirin 50 mg vs. 100 mg in Elderly Cardiovascular Disease Patients

Cardiovascular DiseasesAtherosclerotic Cardiovascular Disease (ASCVD)Secondary Prevention
Peking University First Hospital5,448 enrolled1 locationNCT07542860
Recruiting
Phase 1Phase 2

TB-500 (Thymosin Beta 4 17-23 Fragment) for Cardiovascular Biomarkers in Stable ASCVD

Endothelial DysfunctionAtherosclerotic Cardiovascular Diseases
Hudson Biotech80 enrolled1 locationNCT07487363
Recruiting
Not Applicable

Study of the Determinants of Coronary Atherosclerosis in Familial Hypercholesterolemia (ATHERO-FH Study)

Atherosclerotic Cardiovascular Disease (ASCVD)Familial Hypercholesterolemias
Nantes University Hospital600 enrolled9 locationsNCT06960902
Recruiting
Early Phase 1

Placebo-controlled Study of Single and Multiple Ascending Doses of UDP-003 in Healthy Human Participants and Patients

Atherosclerotic Cardiovascular DiseaseAcute Coronary Syndromes
Cyclarity Therapeutics, Inc.84 enrolled1 locationNCT06813339
Recruiting

A Study Assessing Repatha® in Combination With Standard of Care (SOC) Compared With SOC on Major Cardiovascular Events in Chinese Participants With Atherosclerotic Cardiovascular Disease

Major Cardiovascular EventEstablished Atherosclerotic Cardiovascular Disease
Amgen7,000 enrolled90 locationsNCT06295679
Recruiting
Not Applicable

A Tailored, Optimised, and Person-centred Programme to Promote Lifestyle Modification in People With Metabolic Syndrome

Metabolic SyndromePrimary Prevention of Atherosclerotic Cardiovascular Disease
The University of Hong Kong152 enrolled1 locationNCT06793930
Recruiting
Phase 3

Polypill and Colchicine for Risk Reduction in Atherosclerotic Cardiovascular Disease

Atherosclerotic Cardiovascular Disease (ASCVD)Atherothrombotic Diseases
Hospital do Coracao7,713 enrolled13 locationsNCT06930885
Recruiting

The Coronary Artery Calcium and Troponins in Rheumatoid Arthritis (CAT-RA) Study

Rheumatoid Arthritis (RA)Atherosclerotic Cardiovascular Disease (ASCVD)
Brigham and Women's Hospital120 enrolled1 locationNCT07315997
Recruiting
Phase 1

Fish Oil, Metformin and Heart Health in PCOS

Cardiovascular DiseasePCOSAtherosclerotic Plaque+2 more
University of Alberta146 enrolled3 locationsNCT06424860
Recruiting
Not Applicable

Polygenic Risk Score Implementation and Stratification for Managing Blood Pressure

HypertensionAtherosclerotic Cardiovascular Disease
University of Alabama at Birmingham300 enrolled1 locationNCT06962488
Recruiting

Lipoprotein(a) Levels in Patients With Atherosclerotic Cardiovascular Diseases in Russia

Atherosclerotic Cardiovascular Disease
Novartis Pharmaceuticals2,382 enrolled20 locationsNCT06858332
Recruiting
Not Applicable

A Pragmatic INitiative for LDL-C Management by a CLinical Pharmacist-Led Team Among Atherosclerotic CardiovascUlar DisEase Patients

Atherosclerotic Cardiovascular Disease
Intermountain Health Care, Inc.400 enrolled1 locationNCT06571162